Quick Answer
Abivax S.A. reported Research And Development Expense of $177.76 million for the year ending 2025.
- Abivax S.A. showed an increase of +21.3% in Research And Development Expense from 2024 to 2025.
- This data is from Abivax S.A.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Abivax S.A.'s Research And Development Expense has grown by 272.0%.
- Historical annual values: Fiscal year 2025: $177.76 million | Fiscal year 2024: $146.53 million | Fiscal year 2023: $103.18 million | Fiscal year 2022: $48.30 million | Fiscal year 2021: $47.78 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: